Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00119613
Status:
COMPLETED
Last Update Posted:
2008-08-08
First Post:
2005-07-07
Brief Title:
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer SCLC Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double Blind Placebo-Controlled Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer SCLC Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa when administered with platinum-containing chemotherapy in subjects with previously untreated extensive-stage small cell lung cancer SCLC increases survival
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None